Abstract 1849
Background
Breast cancer is one of the leading cancers for women worldwide. Mammography is the most widely used to screen breast cancer, although it is inaccurate in young women or women with dense breasts in Korea and Asian countries. Since tumor cells are often under extremely high oxidative or hypoxia, it is widely accepted that Trx1 express high level in malignant cells. Trx1 as a biomarker in blood for breast cancer detection by studies of Trx1 gene and protein expression differences in many malignant tissues and bloods from various cancer patients. It has been shown that gene expression level of Trx1 was the highest in breast cancer tissue among many different cancers in contrast to the lowest in normal breast tissue. Therefore, it would be interesting to examine whether the quantitation of Trx1 from blood could be a tool to detect breast cancer and to complement mammography.
Methods
We have developed an ELISA kit quantitating Trx1. Trx1 levels of bloods from 116 normal healthy women, 140 confirmed breast cancer patients with stage from 0 to 4, and each 30 confirmed patients of lung, ovarian, gastric, colorectal, and cervical cancer have been estimated by the kit. The test results were analyzed by ROC curve, one-way ANOVA test, and unpaired t-test.
Results
The mean value of Trx1 level from normal women was 7.506 (U/mL) and that from breast cancer patients was 37.75. The Trx1 level clearly differentiated breast cancers from normal cases with sensitivity of 96.4% and specificity of 99.1% (AUC 0.990, p < 0.001). Each level of Trx1 from lung (16.7), ovarian (15.50), gastric (15.66), colorectal (16.39), and cervical (22.51) cancer was below the cut-off value (22.8 U/mL) for breast cancer detection. We compared normal women to breast cancer patients’ Trx1 levels and BI-RADS categories. Among the normal women, the false positive rate of mammography was 26% whereas that of Trx1 quantitation was 1%. Among the breast cancer patients, the false negative rate of mammography was 24.82% and that of Trx1 quantitation was 3.76%.
Conclusions
These results indicated that the blood level of Trx1 quantitation estimated by the ELISA kit could be an effective and specific modality to detect breast cancer from blood and also could complement current limits of mammography for small and dense breasts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4410 - Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
5077 - Response to Pegylated Liposomal Doxorubicin (PLD) and Weekly Paclitaxel (wpac) in Platinum Resistant (PR) Ovarian Cancer (OC) by BRCA mutation status
Presenter: Louise Bremer
Session: Poster Display session 2
Resources:
Abstract
3483 - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Presenter: Bradley Monk
Session: Poster Display session 2
Resources:
Abstract
5423 - OCTAVE - A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Presenter: Iain McNeish
Session: Poster Display session 2
Resources:
Abstract
1385 - Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
Presenter: Natalie Ngoi
Session: Poster Display session 2
Resources:
Abstract
2090 - Phase 1b/2a study assessing the safety and efficacy of adding AL3818 (Anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
Presenter: David Miller
Session: Poster Display session 2
Resources:
Abstract
1960 - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month Follow-up Results of the Dose Escalation Phase
Presenter: Jermaine Coward
Session: Poster Display session 2
Resources:
Abstract
4288 - Hybrid capture-based genomic profiling of circulating tumor DNA (ctDNA) from patients with ovarian cancer
Presenter: Mi Yang
Session: Poster Display session 2
Resources:
Abstract
3433 - Tumor Microvessel Density for predicting Nintedanib activity: data from the randomized CHIVA trial (a GINECO study)
Presenter: Maud Villemin
Session: Poster Display session 2
Resources:
Abstract
3392 - Post-hoc analysis of the nintedanib exposure-response relationships in the CHIVA trial in advanced ovarian cancer: (a GINECO study)
Presenter: Skerdi HAVIARI
Session: Poster Display session 2
Resources:
Abstract